Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 study
Arvind Dasari(The University of Texas MD Anderson Cancer Center), Cathy Eng(Vanderbilt University), Alberto Sobrero(Ospedale Policlinico San Martino), Josep Tabernero(Deaconess Hospital), Dirk Arnold(Asklepios Klinik Altona), Howard S. Höchster(Rutgers, The State University of New Jersey), Violaine Randrian(Université de Poitiers), Andrew Scott Paulson(Texas Oncology), Jeremy Jones(Mayo Clinic in Florida), Judit Kocsis(Bács-Kiskun Megyei Kórház), Jiří Tomášek(Masaryk Memorial Cancer Institute), Andrea Sartore‐Bianchi(University of Milan), Elena Élez(Vall d'Hebron Hospital Universitari), Toshiki Masuishi(Aichi Cancer Center), Laurence Faugeras(CHU Dinant Godinne UCL Namur), Shivani Nanda, François Ghiringhelli(Inserm), James C. Yao(The University of Texas MD Anderson Cancer Center), Rocio García‐Carbonero(Research Institute Hospital 12 de Octubre), Sara Lonardi(Istituto Oncologico Veneto), Antonio Cubillo Gracián(Hospital Universitario HM Sanchinarro), Taroh Satoh(Osaka University Hospital), Takayuki Yoshino(University of Tsukuba), Tibor Csőszi, Marek Kania, Geoff Chong(Austin Hospital), William R. Schelman, Ardaman Shergill(University of Chicago), Chiara Cremolini(University of Pisa), Michel Ducreux(Université Paris-Saclay), Pilar García‐Alfonso(Hospital General Universitario Gregorio Marañón), Eric Van Cutsem(Universitair Ziekenhuis Leuven), Zhao Yang, John C. Krauss(University of Michigan), Anneli Elme(North Estonia Medical Centre), Ali Bassam(Békés Megyei Központi Kórház), Stefan Kasper(Essen University Hospital)
Cited by 319
Related Papers
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
|New England Journal of Medicine|2013|6.6k
Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors
|Science|2017|5.4k
Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies
|Science Translational Medicine|2014|5.1k
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
|New England Journal of Medicine|2016|5.1k